MedTrace Logo

Evaluation of Mirtazapine and Folic Acid for Schizophrenia:

NCT01263080 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 333

Last updated 2016-08-02

No results posted yet for this study

Summary

Multicentre randomised double-blind, placebo-controlled 2x2 factorial trial investigating the effects of adding mirtazapine and folic acid to existing therapy for patients with schizophrenia

Conditions

Interventions

DRUG

mirtazapine

mirtazapine 30mg QD

DRUG

folic acid placebo

folic acid placebo 1 tablet QD

DRUG

mirtazapine placebo

mirtazapine placebo 1 tablet QD

DRUG

folic acid

folic acid 0.4mg QD

Sponsors & Collaborators

  • Capital Medical University

    lead OTHER

Principal Investigators

  • Gang Wang, M.D. · Beijing Anding Hospital, Capital Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2012-12-31
Completion
2012-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01263080 on ClinicalTrials.gov